Lattice Biologics Stock Performance
| LBLTF Stock | USD 0.0001 0.00 0.00% |
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Lattice Biologics are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Lattice Biologics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Lattice Biologics is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 15.7 K | |
| Total Cashflows From Investing Activities | -592.1 K | |
| Free Cash Flow | -55.9 K |
Lattice |
Lattice Biologics Relative Risk vs. Return Landscape
If you would invest 0.01 in Lattice Biologics on September 28, 2025 and sell it today you would earn a total of 0.00 from holding Lattice Biologics or generate 0.0% return on investment over 90 days. Lattice Biologics is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Lattice, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Lattice Biologics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lattice Biologics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Lattice Biologics, and traders can use it to determine the average amount a Lattice Biologics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| LBLTF |
Based on monthly moving average Lattice Biologics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lattice Biologics by adding Lattice Biologics to a well-diversified portfolio.
Lattice Biologics Fundamentals Growth
Lattice Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Lattice Biologics, and Lattice Biologics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lattice Pink Sheet performance.
| Return On Asset | -0.25 | |||
| Profit Margin | (0.61) % | |||
| Operating Margin | (0.40) % | |||
| Current Valuation | (13.03 K) | |||
| Shares Outstanding | 128.22 M | |||
| Price To Earning | 7.32 X | |||
| Price To Book | 0.13 X | |||
| Price To Sales | 2.61 X | |||
| Revenue | 2.46 M | |||
| EBITDA | (61.24 K) | |||
| Cash And Equivalents | 24.19 K | |||
| Total Debt | 342.94 K | |||
| Book Value Per Share | 0 X | |||
| Cash Flow From Operations | 536.15 K | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 3.02 M | |||
About Lattice Biologics Performance
By analyzing Lattice Biologics' fundamental ratios, stakeholders can gain valuable insights into Lattice Biologics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Lattice Biologics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Lattice Biologics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologic products for use in the field of bone regeneration in dental, spine, and general orthopedic indications worldwide. Its products are used in a range of applications, including enhancing fusion in spine surgery and breast reconstruction post mastectomy, promotion of bone regeneration in foot and ankle surgery, promotion of skull healing following neurosurgery, enhancing wound repair in burn victims, hernia repair, and subchondral bone defect repair in knee and other joint surgeries, as well as sports medicine indications, such as anterior and posterior cruciate ligament repair. Lattice Biologics operates under Medical Devices classification in the United States and is traded on OTC Exchange.Things to note about Lattice Biologics performance evaluation
Checking the ongoing alerts about Lattice Biologics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Lattice Biologics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lattice Biologics generated a negative expected return over the last 90 days | |
| Lattice Biologics has some characteristics of a very speculative penny stock | |
| Lattice Biologics has accumulated 342.94 K in total debt. Lattice Biologics has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Lattice Biologics until it has trouble settling it off, either with new capital or with free cash flow. So, Lattice Biologics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Lattice Biologics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Lattice to invest in growth at high rates of return. When we think about Lattice Biologics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 2.46 M. Net Loss for the year was (1.48 M) with profit before overhead, payroll, taxes, and interest of 1.18 M. |
- Analyzing Lattice Biologics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lattice Biologics' stock is overvalued or undervalued compared to its peers.
- Examining Lattice Biologics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lattice Biologics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lattice Biologics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lattice Biologics' pink sheet. These opinions can provide insight into Lattice Biologics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Lattice Pink Sheet analysis
When running Lattice Biologics' price analysis, check to measure Lattice Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lattice Biologics is operating at the current time. Most of Lattice Biologics' value examination focuses on studying past and present price action to predict the probability of Lattice Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lattice Biologics' price. Additionally, you may evaluate how the addition of Lattice Biologics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |